NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

项目摘要 该补助金支持Dana-Farber/Partners Cancer Care的网络领先学术参与站点（NLAPS） - 一个由研究人员和临床医生组成的社区，致力于通过以下方式减轻美国社会的癌症负担： 为国家临床试验网络（NCTN）的活动贡献科学领导力和患者收益， 国家癌症研究所丹娜法伯/合作伙伴癌症护理包括三个哈佛的主要教学 医院-丹娜-法伯癌症研究所、布里格姆妇女医院和马萨诸塞州总医院 - 该补助金支持这些医院的癌症研究人员和临床医生。的这个民族 研究人员和临床医生在NCTN中有着卓越的领导记录，包括执行 合作小组的领导人、领导国家试验的研究人员和开展试点研究的研究人员 和临床前实验，导致确定的，实践定义的临床试验在NCTN。NLAPS 在NCTN试验中也有着巨大的记录。值得注意的是， 捐款涵盖了美国癌症的全部需求，包括主要癌症类型（乳腺癌，肺癌， 前列腺、结肠直肠和其他）以及不太常见但重要的癌症（头颈部，黑色素瘤， 白血病、多发性骨髓瘤、肉瘤和其他），以及包括药物在内的所有癌症治疗方式。 治疗，放射治疗，手术，生物统计设计，转化科学，以及 症状控制和支持性护理。最新的科学进展出现在 DF/PCC在NCTN的领导地位包括前列腺癌、乳腺癌、白血病、 和黑色素瘤NLAPS拨款对DF/PCC的使命至关重要，并允许其调查人员提供削减 通过创新研究为患者提供边缘治疗，这些研究将定义美国癌症护理的未来。

Project Summary This grant supports Network Lead Academic Participating Site (NLAPS) at Dana-Farber/Partners Cancer Care – a community of investigators and clinicians committed to reduce the burden of cancer in American society by contributing scientific leadership and patient accrual to the National Clinical Trials Network (NCTN) activities of the National Cancer Institute. Dana-Farber/Partners Cancer Care includes three of Harvard's major teaching hospitals – Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital – and the grant supports the cancer researchers and clinicians based at those hospitals. This community of investigators and clinicians has a remarkable track record of leadership in the NCTN including executive leaders of cooperative groups, investigators heading national trials, and researchers who develop pilot studies and preclinical experiments that lead to definitive, practice-defining clinical trials in the NCTN. The NLAPS also has a tremendous record of robust accrual to NCTN trials. Notably, the scientific and accrual contributions cover the full spectrum of cancer need in the US, including major cancer types (breast, lung, prostate, colorectal, and others) as well as less common but important cancers (head and neck, melanoma, leukemia, multiple myeloma, sarcoma and others), and all modalities of cancer treatment including medical therapies, radiation treatments, surgery, biostatistical design, translational science, and innovations in symptom control and supportive care for cancer patients. Recent scientific advances that emerged from DF/PCC leadership in the NCTN include new treatment standards in prostate cancer, breast cancer, leukemia, and melanoma. The NLAPS grant is vital to the mission of DF/PCC and allows its investigators to offer cutting edge treatments to patients through innovative studies that will define the future of cancer care in America.